Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer
Michal Mego(Comenius University Bratislava), James M. Reuben(The University of Texas MD Anderson Cancer Center), Massimo Cristofanilli(Cornell University), Simone Anfossi(The University of Texas MD Anderson Cancer Center), Mario Giuliano(Regione Campania), Evan N. Cohen(The University of Texas MD Anderson Cancer Center), Ugo De Giorgi(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Vicente Valero(The University of Texas MD Anderson Cancer Center), Naoto T. Ueno(Breast Cancer Care), Tamer M. Fouad(The University of Texas MD Anderson Cancer Center), Hui Gao(The University of Texas MD Anderson Cancer Center), Antonio Giordano(Harvard University), Ricardo H. Álvarez(The University of Texas MD Anderson Cancer Center), Wendy A. Woodward(The University of Texas MD Anderson Cancer Center), Sanda Tin(The University of Texas MD Anderson Cancer Center), Gabriel N. Hortobágyi(The University of Texas MD Anderson Cancer Center)
Cited by 72
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
|Cancer Cell|2004|1.9k
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
|New England Journal of Medicine|2015|1.6k